SLC5A2 and heart failure: For example, treatment for one year of 1000 patients with chronic kidney disease and diabetes with an SGLT2 inhibitor was estimated to result in 11 fewer patients developing kidney disease progression, four fewer patients with acute kidney injury, and 11 fewer cardiovascular deaths or hospitalisations for heart failure, and to cause around one episode of ketoacidosis and around one lower limb amputation (figure 5).